Tiny Gems

Friday Feb 20, 2026 - 2:30 pm

InvestorNewsBreaks – GridAI Technologies Corp. (NASDAQ: GRDX) Poised at Convergence of Electrification, EV Growth and AI Demand

GridAI Technologies (NASDAQ: GRDX), a company operating at the intersection of artificial intelligence and energy infrastructure, is positioned for opportunity as the power grid has become a central battleground for the next phase of AI growth. An article discussing this reads, “The company is developing grid and power-management software aimed at hyperscale AI data center campuses. Its core proposition is that the limiting factor for…

Wednesday Feb 11, 2026 - 3:31 pm

InvestorNewsBreaks – GridAI Technologies Corp. (NASDAQ: GRDX) Highlights Growth Strategy at Intersection of AI and Power Management

GridAI Technologies (NASDAQ: GRDX) is focused on advancing opportunities at the intersection of artificial intelligence and energy infrastructure following its acquisition of Grid AI, Inc. “The company recently announced that it had named Marshall Chapin as the CEO of the company’s GridAI, Inc. subsidiary,” an article discussing the company reads. “GridAI, Inc. is developing next-generation grid and power-management software for hyperscale artificial-intelligence (‘AI’) data-center campuses,…

Wednesday Feb 11, 2026 - 2:46 pm

InvestorNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is focused on enhancing established cancer therapies by targeting a fundamental biological pathway involved in tumor survival and resistance. “Rather than developing standalone treatments, LIXTE is advancing a first-in-class approach designed to increase the effectiveness of chemotherapy and immunotherapy across multiple cancer indications,” reads a recent article. “At the center of LIXTE’s strategy is protein phosphatase…

Friday Feb 06, 2026 - 2:39 pm

InvestorNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is leading efforts in addressing some of the pressing challenges in cancer treatment. “Instead of developing standalone cancer drugs, the company is adopting a different strategy aimed at enhancing the overall effectiveness of existing immunotherapy and chemotherapy regimens through a novel biological target,” reads a recent article. “LIXTE’s platform is built on its proprietary LB-100 compound,…

Thursday Dec 04, 2025 - 1:37 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Talks Bold Strategy to Treat GBM in BioMedWire Podcast

CNS Pharmaceuticals (NASDAQ: CNSP) was featured in a BioMedWire Podcast discussing its sharpened focus on glioblastoma multiforme (“GBM”), one of the deadliest and least treatable forms of cancer. In the interview, CEO John Climaco said of GBM, “Patients have very little hope. Our mission is to change that completely, and we think we have the drugs to do it.” An article discussing this reads, “The…

Wednesday Oct 01, 2025 - 2:33 pm

InvestorNewsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Sets Standard in High-Performance E-Boat Space

Vision Marine Technologies Inc. (NASDAQ: VMAR) was featured in a recent article that discusses its positioning and commitment to revolutionizing the boating experience. The company “has long demonstrated its leadership in marine electrification, with its E-Motion(TM) 180E-powered vessel holding the world record for the fastest electric boat. Set at the annual Lake of the Ozarks Shootout in Missouri, the record shows that VMAR’s craft reached…

Friday Jun 13, 2025 - 3:41 pm

InvestorNewsBreaks – SolarBank Corp.’s (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Forest Hill Rd Project Adds to Growing Development Pipeline

Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) was featured in a recent article that discussed its momentum with the development of its Forest Hill Rd solar project in upstate New York. “The 4.584 megawatt DC installation will operate as a community solar facility, contributing renewable energy to the local grid and offering cost savings to approximately 540 homes,”…

Tuesday Jun 10, 2025 - 12:52 pm

InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Taps Biotech Veteran to Lead Next Phase of Growth

Calidi Biotherapeutics (NYSE American: CLDI) recently announced the appointment of Eric Poma, PhD, as its new chief executive officer and member of the board of directors. The company was featured in an article that reads, “As Calidi Biotherapeutics continues to pioneer targeted antitumor virotherapies, the appointment of Dr. Poma as CEO represents a strategic move to harness experienced leadership for the company’s next phase of…

Thursday May 22, 2025 - 2:50 pm

InvestorNewsBreaks – Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) RTNova Shows Promise in Targeted Tumor Therapy

Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors. The innovative platform not only targets cancer cells effectively but also minimizes harm to surrounding healthy tissues, potentially improving treatment outcomes and reducing side effects. As global cancer rates continue to rise, Calidi’s RTNova platform and tumor-specific virotherapy…

Friday May 09, 2025 - 2:51 pm

InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Eyes Game-Changing Approach to Cancer Treatment

Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its innovative RTNova platform, which has successfully delivered transient gene-therapy payloads to targeted tumors. In addition, Calidi’s virotherapy demonstrated efficacy in killing more than 60 different tumor cell lines, showcasing the platform’s potential to revolutionize cancer treatment by enabling both tumor destruction and robust immune activation. “Targeting tumors with a systemic virotherapy with a…

Thursday Apr 17, 2025 - 2:13 pm

InvestorNewsBreaks – SolarBank Corp.’s (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Vision in Action: Building the Grid of Tomorrow

Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., is reinforcing its role in powering the future through solar, battery storage, and EV charging projects. In recent interviews on InvestorBrandNetwork’s Bell2Bell and Electrek’s Quick Charge podcasts, CEO…

Monday Apr 07, 2025 - 3:03 pm

InvestorNewsBreaks – SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Driving Clean Energy Innovation Through Multiple Projects

Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) is a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S. The company recently announced a partnership with Viridi, the industry leader in fail-safe battery energy storage systems (“BESS”), to develop a combined 3.06 megawatt (“MW”) direct current…

Friday Mar 21, 2025 - 1:48 pm

InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI): Poised in the Future of Oncology with Cutting-Edge Treatments

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of research and development of innovative treatments in the field of immuno-oncology. With cancer being the second leading cause of death globally, the company focuses on harnessing antitumor virotherapies and patented technologies designed to protect and potentiate the virotherapy during administration to combat cancer more effectively and with fewer side effects. The…

Friday Mar 14, 2025 - 2:26 pm

InvestorNewsBreaks – Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) Novel Therapies Show Promise Against Aggressive Cancers

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company that is pioneering proprietary technology designed to attack solid tumors, empowering the immune system to combat cancer. The company was featured in a recent article that discussed its platform, which utilizes antitumor virotherapies that selectively infect and kill cancer cells while stimulating the body's immune response. Calidi's pipeline includes three key therapies — RTNova, SuperNova…

Wednesday Mar 05, 2025 - 2:33 pm

InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Stands at the Forefront of Integrating New Oncology Therapies

Calidi Biotherapeutics (NYSE American: CLDI) is leveraging innovative platforms in a commitment to transform cancer treatment using advanced biotechnology. “The company is pioneering therapies that combine stem cells with antitumor viruses to create powerful cancer treatments. Antitumor viruses or virotherapies selectively infect and destroy cancer cells while sparing normal cells and, when paired with stem cells, their therapeutic potential is significantly amplified,” reads a recent…

Tuesday Dec 03, 2024 - 3:41 pm

InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Showcases Platform ‘Designed to Unlock New Possibilities in Cancer Therapy’

Calidi Biotherapeutics (NYSE American: CLDI) is focused on discovering more effective treatments amid projections from the American Cancer Society that 2024 will be the first year ever to see two million people diagnosed with cancer. “Calidi Biotherapeutics’ RTNova (‘CLD-400’) is an innovative systemic antitumor enveloped virotherapy designed to unlock new possibilities in cancer therapy. The platform addresses challenges presented by untargetable and untreatable metastatic diseases…

Friday Sep 20, 2024 - 3:30 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, looks to offer a better alternative to diabetes management and treatment through its patented DehydraTECH(TM) technology. “Lexaria has recently made strides with glucagon-like peptide-1 (‘GLP-1’) studies. It has reported positive interim results from an animal study on diabetes. This milestone best showcases the potential of its patented technology in not only addressing diabetes…

Friday Sep 13, 2024 - 3:27 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 Program

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently released its fiscal report for the third quarter of the 2024 financial year (“Q3, 2024”). “Of note was growth in cash and marketable securities from $1.5 million during the same period in the 2023 financial year to $8.5 million as of May 31, 2024. The company reduced certain R&D expenditures and experienced other savings,” reads a recent article. “Most…

Wednesday Sep 04, 2024 - 1:18 pm

InvestorNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Completes First Shipment of Vehicles Purchased by Volt Mobility through $210M PO

Mullen Automotive (NASDAQ: MULN), an electric vehicle (“EV”) manufacturer, announced the initial shipment of vehicles to fulfill a $210 million purchase contract with Volt Mobility, which is based in the United Arab Emirates (“UAE”). Volt has purchased 3,000 Mullen Class 1 and Class 3 EV cargo vans and trucks to be delivered over a 16-month period. The initial shipment of vehicles represents the first phase…

Tuesday Sep 03, 2024 - 11:32 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Latest BioMedWire Podcast Episode

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is spotlighted in the most recent episode of IBN’s BioMedWire Podcast. During the episode, CNS Pharmaceuticals CEO John Climaco talks with podcast host Carmel Fisher to explain what sets CNSP’s Berubicin and new TPI-287 candidate apart from anything else…

Friday Aug 30, 2024 - 2:45 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) BayMedica Poised as Rare Cannabinoids Drive Market Growth

InMed Pharmaceuticals’ (NASDAQ: INM) subsidiary BayMedica is positioned amid a growing interest in edibles infused with non-intoxicating minor cannabinoids. These lesser-known cannabinoids offer unique properties and potential health benefits, driving significant market growth. The company published a report on the expansion of the minor cannabinoid market in 2023. “The report, based on data from Headset, the largest industry dataset, explores the growth, competition and consumer…

Wednesday Aug 28, 2024 - 2:01 pm

InvestorNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Upgrades More K5 Contracts, Moves Closer to Achieving Key ‘Road to Profitability’ Step

Knightscope (NASDAQ: KSCP), an innovator in robotics and artificial intelligence (“AI”) technologies focused on public safety, is reporting that four more clients have upgraded their existing contracts to include the fifth-generation K5 Autonomous Security Robot (“K5v5”). According to the company, this means that 70% of the KSCP’s K5 operating fleet has advanced to the latest release, bringing the company closer to reaching a key step…

Tuesday Aug 27, 2024 - 1:49 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, is announcing receipt of the first results from human pilot study #2, GLP-1-H24-2. According to the announcement, the company’s DehydraTECH(R)-processed Rybelsus(R) evidenced a trend toward higher overall absorption under fed conditions compared to Rybelsus(R) that was not processed with DehydraTECH. The DehydraTECH-processed Rybelsus(R) evidenced higher semaglutide levels in 17 of the 19 blood…

Monday Aug 26, 2024 - 9:43 am

InvestorNewsBreaks – Evofem Biosciences Inc. (EVFM) Subsidiary Appoints Industry Veteran as Subsidiary President

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising health innovations, has announced a new president for its majority-owned subsidiary, Pearsanta Inc. According to the announcement, Christoper Mitton has been named president of the subsidiary, which focuses on precision health. Mitton has an impressive career of leadership in the medical diagnostics space spanning more than two decades. His experience includes building and…

Thursday Aug 22, 2024 - 2:09 pm

InvestorNewsBreaks – GEMXX Corp. (GEMZ) Expanding Influence in the Global Energy Sector

GEMXX (OTC: GEMZ) recently announced that its collaborator, Latin America Partners (“LEP”), an emerging leader and an independent E&P company involved in exploring significant hydrocarbon reserves in Latin America, has expanded its team. “LEP is guided by Dinesh Kumar Sarraf, the chairman of the board… He leads a team of distinguished energy industry experts who, for decades, have been actively involved in global oil and…

Thursday Aug 22, 2024 - 11:26 am

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive 8-Week Body Weight Results from Ongoing Diabetes Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, is reporting on 8-week body weight results from its ongoing animal study WEIGHT-A24-1. According to the company, this is the only study carried out anywhere in the world today to evaluate the relative performance of liraglutide processed with DehydraTECH. The results show that DehydraTECH-liraglutide is outperforming DehydraTECH-semaglutide. In humans, semaglutide has been shown…

Wednesday Aug 21, 2024 - 1:29 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics (TSX: APLI) (OTC: APLIF) Enter Third Amending Agreement

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising health innovations, has entered into a third amending agreement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF), a biopharmaceutical company focused on developing innovative treatments and vaccines to combat some of the most challenging infectious diseases and potential bioterrorism threats. According to the agreement, Aditxt, through its wholly owned subsidiary Adivir Inc., will…

Wednesday Aug 21, 2024 - 12:14 pm

InvestorNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Announces Expansion of Contract with California Healthcare Provider

Knightscope (NASDAQ: KSCP), an innovator in robotics and artificial intelligence (“AI”) technologies focused on public safety, has received an expanded contract with a long-standing healthcare client. The client, based in California, is contracting for an additional K5 Autonomous Security Robot (“ASR”); the client deployed its first K5 ASR in 2023. The K5 is the Knightscope’s fully autonomous, outdoor robot that provides surveillance 24/7/365. “Healthcare organizations across…

Wednesday Aug 21, 2024 - 9:50 am

InvestorNewsBreaks – Lottery.com Inc. (NASDAQ: LTRY) Reports on Final Terms for S&MI Ltd. Acquisition

Lottery.com (NASDAQ: LTRY), a leading online lottery services provider, has finalized terms for the acquisition of S&MI Ltd., an innovative technology company behind the current Sports.com brand and app. According to the announcement, the total acquisition price will be satisfied with equity of Lottery.com common stock, priced at $3 per share. According to the announcement, the acquisition of S&MI is expected to solidify Sports.com as…

Tuesday Aug 20, 2024 - 1:01 pm

InvestorNewsBreaks – ECGI Holdings Inc. (ECGI) Says Success of Allon Equestrian Apparel Line at AETA Is ‘Pivotal Moment’

ECGI Holdings (OTC: ECGI), a diversified holding company with a unique portfolio in viticulture, hospitality and luxury fashion, is reporting on the success of its Allon equestrian apparel line during the American Equestrian Trade Association (“AETA”) International trade show, which was held in Dallas. According to the company, the launch, which included a range of show coats, show shirts, breeches, safety vest covers and jewelry,…

Monday Aug 19, 2024 - 10:19 am

InvestorNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Continues to Expand Presence in Higher Education Sector with New Vehicle Order

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced the sale of the Mullen THREE, Class 3 EV box truck uplift to the facilities operations unit at Princeton University. The Mullen THREE is expected to support the unit’s campus operations as well as contribute to its overall sustainability goals, including reaching zero emissions for on-campus university service vehicles. According to the announcement,…

Friday Aug 16, 2024 - 3:03 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089 Showing Great Promise in Treating AMD

InMed Pharmaceuticals (NASDAQ: INM), a clinical stage company developing a pipeline of pharmaceutical drug candidates to treat several diseases with a high unmet medical need, is at the forefront of developing innovative treatment for age-related macular degeneration (“AMD”), with its flagship product INM-089 showing great promise. “AMD is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part…

Friday Aug 16, 2024 - 2:30 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Opportunity from First-Ever Work with Tirzepatide Molecule

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently hired a Contract Research Organization (“CRO”) for its third human pilot study. “This marks a milestone for the company, notably since it announced its focus solely on glucagon-like peptide 1 (‘GLP-1’) studies for the 2024 calendar year… This randomized, crossover investigation will evaluate a dual-action GLP-1 + glucose-dependent insulintropic peptide (‘GIP’), specifically…

Thursday Aug 15, 2024 - 9:58 am

InvestorNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Reports on Voting Results of 2024 Annual and Special Meeting of Shareholders

Flora Growth (NASDAQ: FLGC), a consumer-packaged goods leader and pharmaceutical distributor, is reporting on its 2024 Annual and Special Meeting of Shareholders. The meeting. According to the announcement, shareholders voted on and approved all five proposals on the agenda. Proposals included the election of four directors to the company’s board of directors; the reappointment of Davidson & Company LLP, an independent registered public accounting firm,…

Wednesday Aug 14, 2024 - 10:41 am

InvestorNewsBreaks — NextPlat Corp. (NASDAQ: NXPL), Progressive Care (RXMD) Release Q2 2024 Financial Results Showing 474% Revenue Increase

NextPlat (NASDAQ: NXPL), a global e-Commerce provider, has released record financial results for its second fiscal quarter, the period ended June 30, 2024; the results include the consolidation of the operations of its e-commerce business with the results of its healthcare operations, Progressive Care Inc. (OTCQB: RXMD). Highlights of the report indicate the company experienced a 474% increase in consolidated Q2 revenues, which totaled $17 million, and a…

Wednesday Aug 14, 2024 - 9:57 am

InvestorNewsBreaks – Evofem Biosciences Inc. (EVFM) Releases Second-Quarter 2024 Financial Results, Company Update

Evofem Biosciences (OTCQB: EVFM) is reporting on its financial results and corporate update for Q2 2024; the report also included a report on the first half of 2024. Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, entered into a merger agreement with Evofem last year; the agreement was amended and restated in July 2024, with a targeted close for later…

Wednesday Aug 14, 2024 - 9:20 am

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2025 Financial, Corporate Report

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, is reporting its financial results for the first quarter 2025, or the period ended June 30, 2024. The report also included a status update on the company’s pipeline, including fasedienol for the acute treatment of social anxiety…

Tuesday Aug 13, 2024 - 12:37 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Releases Report on Annual Shareholders’ Meeting Activity

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising innovations, is reporting on the results of its recent annual shareholders' meeting. According to the announcement, all nine proposed agenda items were successfully passed. Those proposals include the election of directors, the ratification of auditors, and the issuing of shares for Series B-1 and B-2 convertible preferred stock.In addition, a proposed Equity Line…

Tuesday Aug 13, 2024 - 11:41 am

InvestorNewsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Announces ‘Exceptional Results’ in Q2 2024

Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems, and gaming content, today announced its financial results for the second quarter of 2024 (“Q2 2024”) ended June 30, 2024, and the first half of the year (year to date). According to the announcement, the results demonstrated robust growth and continued operational success. Key numbers included a 75% increase in Q2…

Tuesday Aug 13, 2024 - 11:12 am

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Expansion of Live-Cell Tumor Platform Applications

Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, has expanded the available applications for its platform to account for patient heterogeneity, derisk drug discovery and accelerated pipeline development. The company announced that its findings demonstrate real-world applications of POI’s AI platform to support biomarker discovery, clinical trial optimization and target validation; the platform also offers a proprietary tool that accounts…

InvestorNewsBreaks

NewsBreak Category: Tiny Gems

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions